| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKIb |
| Uniprot No | Q9C010 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-98aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMRTDSSKMTDVESGVANFASSARAGRRNAL PDIQSSAATDGTSDLPLKLEALSVKEDAKEKDEKTTQDQLEKPQNEEK |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为示例性质的参考文献(非真实文献，基于领域常见研究方向构建)：
---
1. **《Recombinant expression and functional characterization of platelet glycoprotein Ib in mammalian cells》**
- 作者：Berndt, M.C. et al.
- 摘要：研究通过哺乳动物细胞系统重组表达血小板糖蛋白Ib(GPIb)，验证其与血管性血友病因子(vWF)的结合活性，并证明其可用于体外血小板黏附功能分析。
2. **《Structural insights into the interaction between recombinant GPIbα and von Willebrand factor》**
- 作者：Luo, S. et al.
- 摘要：利用X射线晶体学解析重组GPIbα与vWF-A1结构域的复合物结构，揭示两者结合的关键氨基酸残基及构象变化，为抗血栓药物设计提供依据。
3. **《Development of a recombinant GPIb-based therapeutic for bleeding disorders》**
- 作者：Dong, J. & Li, R.
- 摘要：开发基于重组GPIb蛋白的融合分子，在动物模型中验证其促进血小板聚集和止血的能力，探索其在遗传性出血性疾病中的治疗潜力。
4. **《PKIb signaling in inflammation: Role of recombinant receptor extracellular domain》**
- 作者：Bergmeier, W. & Hynes, R.O.
- 摘要：通过重组表达PKIb受体胞外段，研究其在炎症信号通路中的作用，发现其可通过竞争性结合配体抑制白细胞过度激活。
---
注：以上文献为假设性示例，实际研究中建议通过PubMed或Web of Science以关键词“recombinant GPIb protein”或“PKIb recombinant”检索真实文献。若用户具体指向某类PKIb(如激酶或受体)，需进一步明确目标蛋白。
PKIb recombinant protein is a biologically engineered form of the protein kinase B (PKB), also known as Akt, which plays a central role in regulating cell survival, proliferation, and metabolism. As a member of the AGC kinase family, PKIb is a key component of the PI3K-Akt signaling pathway, which is frequently dysregulated in cancers, metabolic disorders, and neurodegenerative diseases. The recombinant version is typically produced using heterologous expression systems, such as *E. coli* or mammalian cell lines, to ensure high purity and functional activity for research and therapeutic applications.
The production of PKIb recombinant protein involves cloning the gene encoding the kinase into an expression vector, followed by transfection into host cells. Post-translation modifications, such as phosphorylation at critical residues (e.g., Thr309 and Ser474 in humans), are often necessary to maintain its enzymatic activity. Affinity chromatography tags (e.g., His-tag) are commonly incorporated to facilitate purification. Researchers prioritize optimizing expression conditions to achieve proper folding and avoid aggregation, which is critical for structural studies or inhibitor screening.
In biomedical research, PKIb recombinant protein is widely used to study Akt signaling mechanisms, evaluate drug candidates targeting cancer pathways, and develop diagnostic tools for diseases linked to Akt dysregulation. Its recombinant form offers consistency and scalability compared to native proteins isolated from tissues. Additionally, it serves as a critical reagent in high-throughput assays to identify allosteric inhibitors or activators, aiding the development of targeted therapies. Ongoing efforts focus on engineering mutant variants to explore phosphorylation dynamics or resistance mechanisms, further advancing precision medicine approaches.
×
